Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital bile acid synthesis defect type 2 (BAS defect type 2) is an anomaly of bile acid synthesis characterized by severe and rapidly progressive cholestatic liver disease, and malabsorption of fat and fat-soluble vitamins.
Features include: Diarrhea, Hepatic failure, Abnormality of the coagulation cascade, and Elevated circulating alkaline phosphatase concentration and 8 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 7 | Diarrhea, Hepatic failure, Enlarged liver (hepatomegaly) |
Lab test results | 3 | Elevated circulating alkaline phosphatase concentration, Hyperbilirubinemia, Elevated circulating hepatic transaminase concentration |
Blood and immune system | 2 | Abnormality of the coagulation cascade, Enlarged spleen (splenomegaly) |
Growth and development | 1 | Failure to thrive |
AKR1D1 encodes aldo-keto reductase family 1 member D1 (326 aa). Catalyzes the stereospecific NADPH-dependent reduction of the C4-C5 double bond of bile acid intermediates and steroid hormones carrying a delta(4)-3-one structure to yield an A/B cis-ring junction. Highest expression in Liver (51.7 TPM) and Testis (4.9 TPM).
Congenital bile acid synthesis defect 2 is caused by mutations in the AKR1D1 gene on chromosome 7.
The AKR1D1 protein participates in 4-cholesten-7alpha-ol-3-one is reduced to 5beta-cholestan-7alpha-ol-3-one, 4-cholesten-7alpha,24(S)-diol-3-one is reduced to 5beta-cholestan-7alpha,24(S)-diol-3-one, and 4-cholesten-7alpha, 12alpha-diol-3-one is reduced to 5beta-cholesten-7alpha, 12alpha-diol-3-one pathways.
AKR1D1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 2.2.
Genetic testing for AKR1D1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for congenital bile acid synthesis defect 2 has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
15 publications have been identified in PubMed for congenital bile acid synthesis defect 2. Research spans Case Report / Case Series (36%), Basic Science / Preclinical (21%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 36% |
Laboratory research | 3 | 21% |
Testing and diagnosis research | 2 | 14% |
New treatment approaches | 2 | 14% |
Research summaries | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Muller A (2026). [PMID: 41507260](https://pubmed.ncbi.nlm.nih.gov/41507260/). *Scientific reports*. [Basic Science / Preclinical]
Hudson J (2026). [PMID: 41387259](https://pubmed.ncbi.nlm.nih.gov/41387259/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Ohuchi H (2026). [PMID: 42055732](https://pubmed.ncbi.nlm.nih.gov/42055732/). *Circ J*. [Epidemiology / Natural History]
Khan M (2026). [PMID: 41798580](https://pubmed.ncbi.nlm.nih.gov/41798580/). *Cureus*. [Case Report / Case Series]
Pendleton S (2026). [PMID: 42110141](https://pubmed.ncbi.nlm.nih.gov/42110141/). *JPGN Rep*. [Review / Meta-Analysis]
Degtyareva A (2025). [PMID: 38375845](https://pubmed.ncbi.nlm.nih.gov/38375845/). *Current pediatric reviews*. [Diagnostic / Biomarker]
Alsaleem BM (2025). [PMID: 39897470](https://pubmed.ncbi.nlm.nih.gov/39897470/). *Molecular genetics and metabolism reports*. [Case Report / Case Series]
Al-Hussaini AA (2025). [PMID: 41090521](https://pubmed.ncbi.nlm.nih.gov/41090521/). *Saudi J Gastroenterol*. [Diagnostic / Biomarker]
Ciobanu C (2025). [PMID: 40763044](https://pubmed.ncbi.nlm.nih.gov/40763044/). *American journal of physiology. Gastrointestinal and liver physiology*. [Gene Therapy / Novel Therapeutics]
Thio J (2025). [PMID: 40967667](https://pubmed.ncbi.nlm.nih.gov/40967667/). *BMJ case reports*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 8:13 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about congenital bile acid synthesis defect 2